Ocumension Therapeutics
5DG
Company Profile
Business description
Ocumension Therapeutics is an ophthalmic pharmaceutical platform company identifying, developing, and commercializing ophthalmic therapies. It provides a pharmaceutical total solution to address unmet ophthalmic medical needs in China. Its product candidates include OT-401 (YUTIQ), OT-101, OT-301 (NCX 470), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-202, OT-503 (NCX 4251), OT-701, Ou Qin, Brimonidine tartrate eye drop, 0.5% moxifloxacin eye drop, OT-601-C, OT-302, OT-1301, T-1601, and OT-1602.
Contact
No. 1858 Yinzhongnan Road
Guoxiang Subdistrict
Wuzhong District
SuzhouJiangsu
CHNT: +86 2161493800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
477
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,157.90 | 0.80 | -0.01% |
| CAC 40 | 8,042.95 | 51.25 | -0.63% |
| DAX 40 | 22,891.68 | 107.47 | -0.47% |
| Dow JONES (US) | 41,985.35 | 32.03 | 0.08% |
| FTSE 100 | 8,646.79 | 55.20 | -0.63% |
| HKSE | 23,898.40 | 208.68 | 0.88% |
| NASDAQ | 17,784.05 | 92.42 | 0.52% |
| Nikkei 225 | 37,608.49 | 68.57 | -0.18% |
| NZX 50 Index | 12,128.21 | 14.67 | 0.12% |
| S&P 500 | 5,667.56 | 4.67 | 0.08% |
| S&P/ASX 200 | 7,936.90 | 5.70 | 0.07% |
| SSE Composite Index | 3,370.03 | 5.20 | 0.15% |